Chitosan nanoparticles can deliver drugs to their specific target site and release them over a long period. In current corona crisis, chitosan nanoparticles could be one way to release potential COVID-19 drugs specifically in the lungs of affected patients. A potential drug delivery system for the treatment of SARS-CoV-2 infected persons is Novochizol™, consisting of chitosan-based nanoparticles.
The company Bioavanta-Bosti developed the production of Novochizol™. A two-step activation of chitosan and the addition of a potential Covid-19 active ingredient could produce nanoparticles that are ideal for intra-pulmonary drug release. Therefore the active substances could be released locally, thus inhibiting the inflammatory reaction and preventing damage to lung tissue. In current studies of Novochizol™ aerosols with other drugs (e.g. Losartan), the manufacturers have already been able to determine the successful drug release from therapeutic doses over 25 minutes to 3 hours. Bioavanta-Bosti is currently looking for partners in developing effective therapeutic solutions for the treatment of COVID-19 patients.
More information can be found here: